Last reviewed · How we verify
Moderately to severely active ulcerative colitis
Approved treatments
- OMVOH · ELI LILLY AND CO
- Omvoh · Eli Lilly Nederland B.V.
MIRIKIZUMAB blocks the activity of Interleukin-23, a protein involved in inflammation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderately to severely active ulcerative colitis patent landscape — cliff calendar, originator estates, attackable patents
- Moderately to severely active ulcerative colitis treatment landscape brief
- Moderately to severely active ulcerative colitis treatment updates RSS
Frequently asked questions about Moderately to severely active ulcerative colitis
What drugs treat Moderately to severely active ulcerative colitis?
Tracked treatments include OMVOH, Omvoh.
What is the treatment for Moderately to severely active ulcerative colitis?
Standard treatment for Moderately to severely active ulcerative colitis includes OMVOH, Omvoh. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderately to severely active ulcerative colitis patent cliff · Moderately to severely active ulcerative colitis CI report
- Treatment: OMVOH · ELI LILLY AND CO
- Treatment: Omvoh · Eli Lilly Nederland B.V.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing